{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:55:32Z","timestamp":1788839732303,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ejca.2020.08.021","type":"journal-article","created":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T20:21:42Z","timestamp":1600806102000},"page":"59-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy"],"prefix":"10.1016","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2020-2369","authenticated-orcid":false,"given":"Angelina","family":"Tjokrowidjaja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val","family":"Gebski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Gladieff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Ledermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Penson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Oza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Korach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Huzarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1683-550X","authenticated-orcid":false,"given":"Luis","family":"Manso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Pisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Asher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2763-5949","authenticated-orcid":false,"given":"Sarah J.","family":"Lord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Ik","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Yun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjoung-Won","family":"Park-Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabe","family":"Sonke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Weon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Pujade-Lauraine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.ejca.2020.08.021_bib1","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1200\/JCO.2004.10.028","article-title":"Should CA-125 response criteria Be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?","volume":"22","author":"Gronlund","year":"2004","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2020.08.021_bib2","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.1996.14.5.1545","article-title":"Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125","volume":"14","author":"Rustin","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.08.021_bib3","series-title":"Ovarian cancer including fallopian tube cancer and primary peritoneal cancer","year":"2019"},{"key":"10.1016\/j.ejca.2020.08.021_bib4","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.ejca.2020.08.021_bib5","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/jnci\/92.18.1534","article-title":"Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup","volume":"92","author":"Vergote","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2020.08.021_bib6","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/oxfordjournals.annonc.a010602","article-title":"Defining progression of ovarian carcinoma during follow-up according to CA-125: a North Thames Ovary Group study","volume":"7","author":"Rustin","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.08.021_bib7","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.08.021_bib8","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.08.021_bib9","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2020.08.021_bib10","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.08.021_bib11","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.08.021_bib12","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonzalez-Martin","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.08.021_bib13","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"},{"issue":"9747","key":"10.1016\/j.ejca.2020.08.021_bib14","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(10)61268-8","article-title":"Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): a randomised trial","volume":"376","author":"Rustin","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2020.08.021_bib15","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/oxfordjournals.annonc.a057754","article-title":"The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer","volume":"1","author":"Van der Burg","year":"1990","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2020.08.021_bib16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1200\/JCO.2005.01.2757","article-title":"Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide","volume":"24","author":"Rustin","year":"2006","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2020.08.021_bib17","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/bjc.2011.593","article-title":"CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial","volume":"106","author":"Alexandre","year":"2012","journal-title":"Br J Canc"},{"issue":"24","key":"10.1016\/j.ejca.2020.08.021_bib18","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1200\/JCO.2006.09.4540","article-title":"An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy","volume":"25","author":"Liu","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.08.021_bib19","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1093\/annonc\/mdw238","article-title":"Poor concordance between CA-125 and RECIST in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial","volume":"27","author":"Lindemann","year":"2016","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2020.08.021_bib20","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1634\/theoncologist.2015-0268","article-title":"Patient counseling and management of symptoms during olaparib therapy for recurrent ovarian cancer","volume":"21","author":"Moore","year":"2016","journal-title":"Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2020.08.021_bib21","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.6000","article-title":"Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: final analysis of AGO DESKTOP III\/ENGOT-ov20","volume":"38","author":"Du Bois","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2020.08.021_bib22","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1054\/bjoc.2001.1787","article-title":"Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy","volume":"84","author":"Tuxen","year":"2001","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejca.2020.08.021_bib23","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1006\/gyno.2000.5787","article-title":"Declining CA-125 in an ovarian cancer patient with progression of measurable disease: a rational hypothesis for discordant results","volume":"77","author":"Markman","year":"2000","journal-title":"Gynecol Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492030472X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492030472X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:28:11Z","timestamp":1760732891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492030472X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":23,"alternative-id":["S095980492030472X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.08.021","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.08.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}